Research ArticleOriginal Article
Open Access

Evaluation of the effects of different treatment modalities on angiogenesis in heart failure patients with reduced/mid-range ejection fraction via VEGF and sVEGFR-1

Ismail Erturk, Kenan Saglam, Sadi Elasan, Musa B. Aykan, Ramazan Acar, Fatih Yesildal, Fevzi N. Aydin and Taner Ozgurtas
Saudi Medical Journal October 2018, 39 (10) 1028-1034; DOI: https://doi.org/10.15537/smj.2018.10.22946

References

  1. ↵
    1. McMurray JJ,
    2. Adamopoulos S,
    3. Anker SD,
    4. Auricchio A,
    5. Böhm M,
    6. Dickstein K,
    7. et al.
    (Jul, 2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787–1847.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Ponikowski P,
    2. Voors AA,
    3. Anker SD,
    4. Bueno H,
    5. Cleland JGF,
    6. Coats AJS,
    7. et al.
    (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2200.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Xu B,
    2. Li H
    (2015) Brain mechanisms of sympathetic activation in heart failure: Roles of the renin angiotensin system, nitric oxide and pro inflammatory cytokines (Review). Mol Med Rep 12:7823–7829.
    OpenUrl
  4. ↵
    1. Tanai E,
    2. Frantz S
    (2015) Pathophysiology of Heart Failure. Compr Physiol 6:187–214.
    OpenUrl
  5. ↵
    1. Ferrara N
    (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527–543.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Kaza E,
    2. Ablasser K,
    3. Poutias D,
    4. Griffiths ER,
    5. Saad FA,
    6. Hofstaetter JG,
    7. del Nido PJ,
    8. Friehs I
    (2011) Up-regulation of soluble vascular endothelial growth factor receptor-1 prevents angiogenesis in hypertrophied myocardium. Cardiovasc Res 89:410–418.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Wada T,
    2. Jesmin S,
    3. Gando S,
    4. Yanagida Y,
    5. Mizugaki A,
    6. Sultana SN,
    7. et al.
    (2012) Angiogenic factors and their soluble receptors predict organ dysfunction and mortality in post cardiac arrest syndrome. Crit Care 16:R171.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Failla CM,
    2. Carbo M,
    3. Morea V
    (2018) Positive and negative regulation of angiogenesis by soluble vascular endothelial growth factor receptor-1. Int J Mol Sci 19:E1306.
    OpenUrl
  9. ↵
    1. Gao M,
    2. Lu X,
    3. Chen W,
    4. Xiao GH,
    5. Zhang Y,
    6. Yu R,
    7. Li J
    (2018) Randomized clinical trial of physiological ischemic training for patients with coronary heart disease complicated with heart failure: Safety of training, VEGF of peripheral blood and quality of life. Exp Ther Med 16:260–264.
    OpenUrl
    1. Lottonen-Raikaslehto L,
    2. Rissanen R,
    3. Gurzeler E,
    4. Merentie M,
    5. Huusko J,
    6. Schneider JE,
    7. et al.
    (2017) Left ventricular remodeling leads to heart failure in mice with cardiac-specific overexpression of VEGF-B167: echocardiography and magnetic resonance imaging study. Physiol Rep 5:e13096.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Kobusiak-Prokopowicz M,
    2. Jołda-Mydłowska B,
    3. Grzebieniak T,
    4. Początek K,
    5. Mysiak A
    (2015) Expression of proinflammatory factors, proangiogenic factors and endostatin in patients with heart failure and different grades of collateral circulation development. Adv Clin Exp Med 24:987–994.
    OpenUrl
  12. ↵
    1. Lottonen-Raikaslehto L,
    2. Rissanen R,
    3. Gurzeler E,
    4. Merentie M,
    5. Huusko J,
    6. Schneider JE,
    7. et al.
    (2017) Left ventricular remodeling leads to heart failure in mice with cardiac-specific overexpression of VEGF-B167: echocardiography and magnetic resonance imaging study. Physiol Rep 5:e13096.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Patel JV,
    2. Abraheem A,
    3. Chackathayil J,
    4. Gunning M,
    5. Creamer J,
    6. Hughes EA,
    7. Lip GY
    (2009) J Intern Med 265:562–567.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Wada T,
    2. Jesmin S,
    3. Gando S,
    4. Sultana SN,
    5. Zaedi S,
    6. Yokota H
    (2012) Using angiogenic factors and their soluble receptors to predict organ dysfunction in patients with disseminated intravascular coagulation associated with severe trauma. Crit Care 16:R63.
    OpenUrlPubMed
  15. ↵
    1. Skibsted S,
    2. Jones AE,
    3. Puskarich MA,
    4. Arnold R,
    5. Sherwin R,
    6. Trzeciak S,
    7. Schuetz P,
    8. Aird WC,
    9. Shapiro NI
    (2013) Biomarkers of endothelial cell activation in early sepsis. Shock 39:427–432.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Dumnicka P,
    2. Sporek M,
    3. Mazur-Laskowska M,
    4. Ceranowicz P,
    5. Kuźniewski M,
    6. Drożdż R,
    7. et al.
    (2016) Serum soluble fms-like tyrosine kinase 1 (sflt-1) predicts the severity of acute pancreatitis. Int J Mol Sci 17:2038.
    OpenUrl
  17. ↵
    1. Lam PH,
    2. Gupta N,
    3. Dooley DJ,
    4. Singh S,
    5. Deedwania P,
    6. Zile MR,
    7. et al.
    (2018) Role of high-dose beta-blockers in patients with heart failure with preserved ejection fraction and elevated heart rate: high-dose beta-blocker and outcomes in HFpEF. Am J Med 1:pii: S0002-9343(18)30731-9.
  18. ↵
    1. Lund LH,
    2. Benson L,
    3. Dahlström U,
    4. Edner M,
    5. Friberg L
    (2014) Association between use of ß-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA 312:2008–20018.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Ding Q,
    2. Tian XG,
    3. Li Y,
    4. Wang QZ,
    5. Zhang CQ
    (2015) Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway. World J Gastroenterol 21:9566–9576.
    OpenUrl
  20. ↵
    1. Pan WK,
    2. Li P,
    3. Guo ZT,
    4. Huang Q,
    5. Gao Y
    (2015) Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway. Pediatr Blood Cancer 62:1414–1420.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Zaphiriou A,
    2. Robb S,
    3. Murray-Thomas T,
    4. Mendez G,
    5. Fox K,
    6. McDonagh T,
    7. et al.
    (2005) The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 7:537–541.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Goetze JP,
    2. Gore A,
    3. Møller CH,
    4. Steinbrüchel DA,
    5. Rehfeld JF,
    6. Nielsen LB
    (2004) Acute myocardial hypoxia increases BNP gene expression. FASEB J 18:1928–1930.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Kameda R,
    2. Yamaoka-Tojo M,
    3. Makino A,
    4. Wakaume K,
    5. Nemoto S,
    6. Kitasato L,
    7. et al.
    (2013) Soluble Fms-like tyrosine kinase 1 is a novel predictor of brain natriuretic peptide elevation. Int Heart J 54:133–139.
    OpenUrl
  24. ↵
    1. Nielsen OW,
    2. Cowburn PJ,
    3. Sajadieh A,
    4. Morton JJ,
    5. Dargie H,
    6. McDonagh T
    (2007) Value of BNP to estimate cardiac risk in patients on cardioactive treatment in primary care. Eur J Heart Fail 9:1178–1185.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Pawlak K,
    2. Ulazka B,
    3. Mysliwiec M,
    4. Pawlak D
    (2012) Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis? Transl Res 160:346–354.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section